Characterization of the likelihood continual reassessment method

Biometrika

Volumn 101, Issue 3, 2014, Pages 599-612

  Jia, Xiaoyu ^a   Lee, Shing M ^b   Cheung, Ying Kuen ^b  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Adaptive design; Clinical trial; Coherence; Dose finding; Indifference interval

Indexed keywords

EID: 84907361280     PISSN: 00063444     EISSN: 14643510     Source Type: Journal    
DOI: 10.1093/biomet/asu012     Document Type: Article

References (18)

1. CHEUNG, Y. K. (2005). Coherence principles in dose-finding studies. Biometrika 92, 863-73.
2. CHEUNG, Y. K. (2010). Stochastic approximation and modern model-based designs for dose finding clinical trials. Statist. Sci. 25, 191-201.
3. CHEUNG, Y. K. (2011). Dose Finding by the Continual Reassessment Method. New York: Chapman & Hall.
4. CHEUNG, Y. K. (2013). dfcrm: Dose-Finding by the Continual Reassessment Method. R package version 0.2-2.
5. CHEUNG, Y. K. & CHAPPELL, R. (2002). A simple technique to evaluate model sensitivity in the continual reassessment method. Biometrics 58, 671-4.
6. ELKIND, M. S., SACCO, R. L., MACARTHUR, R. B., FINK, D. J., PEERSCHKE, E., ANDREWS, H., NEILS, G., STILLMAN, J., CHONG, J., CONNOLLY, S., CORPORAN, T., LEIFER, D. & CHEUNG, K. (2008). The Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART): An adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischemic stroke. Int. J. Stroke 3, 210-8.
7. FARIES, D. (1994). Practical modifications of the continual reassessment method for phase I cancer trials. J. Biopharm. Statist. 4, 147-64.
8. GODAMBE, V. P. (1991). Orthogonality of estimating functions and nuisance parameters. Biometrika 78, 143-51.
9. GOODMAN, S. N., ZAHURAK, M. L. & PIANTADOSI, S. (1995). Some practical improvements in the continual reassessment method for phase I studies. Statist. Med. 14, 1149-61.
10. IASONOS, A., ZOHAR, S. & O'QUIGLEY, J. (2011). Incorporating lower grade toxicity information into dose finding designs. Clin. Trials 8, 370-9.
11. LEE, S. M., CHENG, B. & CHEUNG, Y. K. (2011). Continual reassessment method with multiple toxicity constraints. Biostatistics 12, 386-98.
12. LEE, S. M. & CHEUNG, Y. K. (2009). Model calibration in the continual reassessment method. Clin. Trials 6, 227-38.
13. O'QUIGLEY J., PEPE, M. & FISHER, L. (1990). Continual reassessment method: A practical design for phase I clinical trials in cancer. Biometrics 46, 33-48.
14. O'QUIGLEY, J. & SHEN, L. Z. (1996). Continual reassessment method: A likelihood approach. Biometrics 52, 673-84.
15. R Development Core Team (2014). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. http://www. R-project.org.
16. SHEN, L. Z. & O'QUIGLEY, J. (1996). Consistency of continual reassessment method under model misspecification. Biometrika 83, 395-405.
17. STORER, B. E. (1989). Design and analysis of phase I clinical trials. Biometrics 45, 925-37.
18. VAN METER, E. M., GARRETT-MAYER, E. & BANDYOPADHYAY, D. (2012). Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method. Clin. Trials 9, 303-13.